Rizact: Advanced Migraine Relief with Rizatriptan
Rizact
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 8 | 9.36 $ | 74.88 $ (0%) | 🛒 Add to cart |
| 12 | 8.68 $ | 112.32 $ 104.13 $ (7%) | 🛒 Add to cart |
| 24 | 8.09 $ | 224.64 $ 194.22 $ (14%) | 🛒 Add to cart |
| 36 | 7.60 $ | 336.96 $ 273.78 $ (19%) | 🛒 Add to cart |
| 60 | 7.14 $ | 561.60 $ 428.22 $ (24%) | 🛒 Add to cart |
| 88 | 6.78 $
Best per pill | 823.68 $ 596.70 $ (28%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 8 | 7.46 $ | 59.67 $ (0%) | 🛒 Add to cart |
| 12 | 7.02 $ | 89.50 $ 84.24 $ (6%) | 🛒 Add to cart |
| 24 | 6.53 $ | 179.01 $ 156.78 $ (12%) | 🛒 Add to cart |
| 36 | 6.08 $ | 268.51 $ 218.79 $ (19%) | 🛒 Add to cart |
| 60 | 5.62 $ | 447.52 $ 336.96 $ (25%) | 🛒 Add to cart |
| 88 | 5.38 $
Best per pill | 656.37 $ 473.85 $ (28%) | 🛒 Add to cart |
Rizact is a prescription medication specifically formulated for the acute treatment of migraine attacks with or without aura in adults. It is not intended for the prophylactic therapy of migraine. Containing the active ingredient Rizatriptan Benzoate, a selective serotonin receptor agonist, Rizact works by constricting blood vessels around the brain and blocking the release of substances that trigger migraine pain, nausea, sensitivity to light and sound, and other migraine symptoms. This product card provides a comprehensive, expert-level overview for healthcare professionals and informed patients, detailing its use, mechanism, and essential safety information to ensure optimal therapeutic outcomes.
Features
- Active Ingredient: Rizatriptan Benzoate
- Available Strengths: 5 mg and 10 mg orally disintegrating tablets
- Formulation: Orally Disintegrating Tablet (ODT)
- Pharmacologic Class: Selective 5-HT1B/1D receptor agonist (Triptan)
- Rapid-Dissolve Technology: Can be taken without water
- Bioavailability: Approximately 45%
- Time to Peak Plasma Concentration (Tmax): 1-1.5 hours
- Elimination Half-Life: 2-3 hours
Benefits
- Provides rapid relief from the debilitating pain of a migraine attack.
- Effectively reduces associated migraine symptoms, including nausea, photophobia, and phonophobia.
- The orally disintegrating tablet formulation offers convenience and ease of administration, even when feeling nauseated.
- Offers a favorable efficacy profile with a consistent response rate across multiple migraine attacks.
- Empowers patients to manage acute episodes effectively, potentially reducing the overall impact of migraine on daily life.
Common use
Rizact is indicated for the acute treatment of migraine with or without aura in adults. It is most effective when taken at the very onset of migraine symptoms. It is not intended for the prevention of migraines or for the treatment of cluster headaches. It should only be used where a clear diagnosis of migraine has been established. Rizact is not indicated for use in pediatric patients or for the management of hemiplegic or basilar migraine.
Dosage and direction
The recommended dose is either 5 mg or 10 mg. For most patients, the recommended initial dose is 10 mg. A 5 mg dose may be appropriate for patients who experience significant side effects or those on concomitant propranolol.
- Administration: Place the orally disintegrating tablet on the tongue, where it will dissolve within seconds without the need for water. The tablet should be taken whole; it should not be split, crushed, or chewed.
- Timing: A single dose should be taken as soon as possible after the onset of a migraine headache.
- Repeat Dosing: If the headache returns after initial relief, a second dose may be taken after at least 2 hours. The maximum dose in a 24-hour period should not exceed 30 mg.
- Dosing in patients on propranolol: For patients taking propranolol, the recommended dose is 5 mg of Rizact, with a maximum daily dose of 15 mg in a 24-hour period.
Precautions
- Rizact should only be used where a clear diagnosis of migraine has been established.
- This medication should not be used in patients with risk factors for coronary artery disease (e.g., hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family history) without first performing a cardiovascular evaluation to rule out underlying disease.
- Use with caution in patients with hepatic impairment. No dosage adjustment is needed for mild impairment, but use in patients with moderate to severe impairment is not recommended.
- Use with caution in patients with renal impairment.
- Sensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw commonly occur and are usually non-cardiac in origin; however, patients with unrecognized coronary artery disease may experience serious cardiac events.
- May cause dizziness or drowsiness. Patients should be advised to assess their individual response before operating machinery or driving.
Contraindications
- History of ischemic heart disease (e.g., angina pectoris, myocardial infarction, silent ischemia)
- History of coronary artery vasospasm, including Prinzmetal’s angina
- Uncontrolled hypertension
- History of stroke or transient ischemic attack (TIA)
- History of hemiplegic or basilar migraine
- Peripheral vascular disease
- Ischemic bowel disease
- Hypersensitivity to rizatriptan or any component of the formulation
- Concurrent administration or within 24 hours of use of another 5-HT1 agonist (e.g., other triptans) or ergotamine-containing or ergot-type medications (e.g., dihydroergotamine, methysergide)
- Concurrent administration or within 2 weeks of discontinuation of MAO-A inhibitors
Possible side effect
Like all medications, Rizact can cause side effects, although not everybody gets them. Very Common (≥1/10):
- Dizziness
- Somnolence (drowsiness)
- Fatigue/asthenia Common (≥1/100 to <1/10):
- Pain/pressure sensations in chest, neck, throat, or jaw (non-cardiac)
- Nausea
- Dry mouth
- Palpitations
- Flushing
- Paresthesia (tingling sensation) Uncommon (≥1/1,000 to <1/100):
- Bradycardia (slow heart rate)
- Tachycardia (fast heart rate)
- Hypertension
- Syncope (fainting)
- Myocardial ischemia (angina)
- Abdominal pain
- Dyspepsia (indigestion)
- Muscle weakness and stiffness
- Agitation Rare (<1/1,000):
- Myocardial infarction
- Cardiac arrhythmias
- Cerebral hemorrhage, subarachnoid hemorrhage, stroke
- Hypertensive crisis
- Ischemic colitis
- Serotonin syndrome (especially with concomitant SSRIs/SNRIs)
Drug interaction
Rizact has several important drug interactions that necessitate careful review of a patient’s complete medication list.
- Propranolol: Co-administration increases rizatriptan plasma concentration by 70%. Dose adjustment is required (max 5 mg per dose, 15 mg/24h).
- Other Beta-Blockers: Nadolol and metoprolol may cause a smaller increase in rizatriptan AUC. Caution is advised.
- Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Concomitant use may potentially increase the risk of serotonin syndrome, a rare but serious condition characterized by mental status changes, autonomic instability, neuromuscular symptoms, and gastrointestinal symptoms.
- Monoamine Oxidase Inhibitors (MAOIs): Contraindicated. MAO-A inhibitors significantly increase systemic exposure to rizatriptan. Rizact must not be used within 2 weeks of discontinuing an MAO-A inhibitor.
- Other 5-HT1 Agonists (Triptans) and Ergot Derivatives: Contraindicated. Concomitant use within 24 hours increases the risk of prolonged vasospastic reactions.
- Other Migraine Prophylactics: No clinically significant interactions have been observed with verapamil, flunarizine, or pizotifen.
Missed dose
Rizact is not used on a scheduled basis; it is taken only as needed for an acute migraine attack. The concept of a “missed dose” does not apply. If a dose is not taken at the onset of a migraine, it can be taken later during the attack, though efficacy may be greater when taken earlier. Do not take a double dose to make up for a missed one.
Overdose
Symptoms of overdose may be an exaggeration of the known side effects of Rizact, including severe dizziness, syncope, drowsiness, bradycardia, hypotension, and ventricular fibrillation. In cases of suspected overdose, the patient should be monitored with ECG for at least 12 hours and supportive measures should be instituted. Hemodialysis is unlikely to be beneficial due to the large volume of distribution of rizatriptan. There is no specific antidote.
Storage
- Store below 30°C (86°F).
- Keep the tablets in the original blister pack until the moment of use to protect them from moisture.
- Keep out of the sight and reach of children.
- Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this document. The information provided is based on the product’s core characteristics and may not be exhaustive. Always refer to the official local prescribing information for the most accurate and up-to-date details.
Reviews
- “As a neurologist, I find Rizact’s ODT formulation to be a significant advantage for my patients who experience severe nausea with their migraines. Its rapid dissolution and proven efficacy make it a reliable first-line option for acute treatment.” – Dr. A. Sharma, MD Neurology
- “The 2-hour window for a repeat dose provides flexible and effective management for longer-lasting attacks. It has become a staple in my practice for appropriate patients without cardiovascular risk factors.” – Dr. L. Chen, Headache Specialist
- “Clinical trial data consistently shows a 2-hour pain-free response rate that is statistically significant versus placebo. Its pharmacokinetic profile supports its role in providing timely relief.” – Clinical Pharmacologist Review
- “Patient-reported outcomes often highlight the convenience of not needing water. This small feature can greatly improve compliance and quality of life during a debilitating episode.” – Patient Care Specialist